

Accepted Manuscript

Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective

John L. Vahle, Ulf Anderson, Eric A.G. Blomme, Jean-Christophe Hoflack, Daniel P. Stiehl



PII: S0273-2300(18)30111-9

DOI: [10.1016/j.yrtph.2018.04.011](https://doi.org/10.1016/j.yrtph.2018.04.011)

Reference: YRTPH 4113

To appear in: *Regulatory Toxicology and Pharmacology*

Received Date: 21 February 2018

Revised Date: 12 April 2018

Accepted Date: 14 April 2018

Please cite this article as: Vahle, J.L., Anderson, U., Blomme, E.A.G., Hoflack, J.-C., Stiehl, D.P., Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective, *Regulatory Toxicology and Pharmacology* (2018), doi: 10.1016/j.yrtph.2018.04.011.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Use of Toxicogenomics in Drug Safety Evaluation: Current Status and an Industry Perspective**

2

3 John L. Vahle^a, Ulf Anderson^b, Eric A.G. Blomme^c, Jean-Christophe Hoflack^d, Daniel P. Stiehl^e

4 ^a Lilly Research Laboratories, Indianapolis, IN

5 ^b AstraZeneca, Drug Safety & Metabolism, Mölndal, Sweden

6 ^c AbbVie, Global Preclinical Safety, North Chicago, IL, USA

7 ^d F Hoffmann La Roche, Pharma Research and Early Development, Roche Innovation Center

8 Basel, CH

9 ^e Novartis Pharma AG, Translational Medicine at the Novartis Institutes of Biomedical Research,

10 Basel, Switzerland

11

12 *The authors represent a sub-group of the European Federation of Pharmaceutical Industries and*
13 *Associations (EFPIA) preclinical development expert group that conducted the survey and*
14 *sponsored this work.*

15

16 Corresponding Author

17 John L. Vahle

18 Eli Lilly and Company

19 Indianapolis, IN 46285

20 317.277.9649

21 jvahle@lilly.com

22

Download English Version:

<https://daneshyari.com/en/article/8551016>

Download Persian Version:

<https://daneshyari.com/article/8551016>

[Daneshyari.com](https://daneshyari.com)